BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 10351990)

  • 1. Measurement of the complex between prostate-specific antigen and alpha1-protease inhibitor in serum.
    Zhang WM; Finne P; Leinonen J; Vesalainen S; Nordling S; Stenman UH
    Clin Chem; 1999 Jun; 45(6 Pt 1):814-21. PubMed ID: 10351990
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization and determination of the complex between prostate-specific antigen and alpha 1-protease inhibitor in benign and malignant prostatic diseases.
    Zhang WM; Finne P; Leinonen J; Stenman UH
    Scand J Clin Lab Invest Suppl; 2000; 233():51-8. PubMed ID: 11317942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA.
    Jung K; Brux B; Lein M; Knäbich A; Sinha P; Rudolph B; Schnorr D; Loening SA
    Urology; 1999 Jun; 53(6):1160-7; discussion 1167-8. PubMed ID: 10367846
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prostate-specific antigen forms a complex with and cleaves alpha 1-protease inhibitor in vitro.
    Zhang WM; Leinonen J; Kalkkinen N; Stenman UH
    Prostate; 1997 Oct; 33(2):87-96. PubMed ID: 9316649
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma.
    Recker F; Kwiatkowski MK; Piironen T; Pettersson K; Lümmen G; Wernli M; Wiefelspütz J; Graber SF; Goepel M; Huber A; Tscholl R
    Cancer; 1998 Dec; 83(12):2540-7. PubMed ID: 9874461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the clinical validity of free prostate-specific antigen, alpha-1 antichymotrypsin-bound prostate-specific antigen and complexed prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Petras T; Stephan C; Brux B; Sinha P; Winkelmann B; Schnorr D; Loening S
    Eur Urol; 2001 Jan; 39(1):57-64. PubMed ID: 11173940
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate-specific antigen and its complexes with alpha 1-antichymotrypsin in the plasma of patients with prostatic disease.
    España F; Martínez M; Sánchez-Cuenca J; Vera CD; Estellés A; Jiménez-Cruz JF
    Eur Urol; 1996; 30(4):512-8. PubMed ID: 8977078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Hammerer P; Graefen M; Semjonow A; Stieber P; Ossendorf M; Luboldt HJ; Brux B; Stephan C; Schnorr D; Loening SA
    Prostate; 2001 May; 47(2):77-84. PubMed ID: 11340629
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual-label immunoassay for simultaneous measurement of prostate-specific antigen (PSA)-alpha1-antichymotrypsin complex together with free or total PSA.
    Zhu L; Leinonen J; Zhang WM; Finne P; Stenman UH
    Clin Chem; 2003 Jan; 49(1):97-103. PubMed ID: 12507965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Proximity ligation measurement of the complex between prostate specific antigen and alpha1-protease inhibitor.
    Zhu L; Koistinen H; Landegren U; Stenman UH
    Clin Chem; 2009 Sep; 55(9):1665-71. PubMed ID: 19643837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK; Recker F; Piironen T; Pettersson K; Otto T; Wernli M; Tscholl R
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Generation of PSA-ACT-specific monoclonal antibodies and their application in a sandwich immunoassay.
    Wang TJ; Linton HJ; Payne J; Rittenhouse HG; Chan DW; Partin AW; Wolfert RL; Kuus-Reichel K
    Hybridoma; 1999 Dec; 18(6):535-41. PubMed ID: 10626683
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis.
    Lein M; Jung K; Elgeti U; Brux B; Sinha P; Schnorr D; Loening SA
    Anticancer Res; 2000; 20(6D):4997-5001. PubMed ID: 11326657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications.
    Jung K; Brux B; Lein M; Rudolph B; Kristiansen G; Hauptmann S; Schnorr D; Loening SA; Sinha P
    Clin Chem; 2000 Jan; 46(1):47-54. PubMed ID: 10620571
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Free/total prostate-specific antigen ratio--hope and controversies.
    Ravery V; Boccon-Gibod L
    Eur Urol; 1997; 31(4):385-8. PubMed ID: 9187894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Double-label time-resolved immunofluorometric assay of prostate-specific antigen and of its complex with alpha 1-antichymotrypsin.
    Leinonen J; Lövgren T; Vornanen T; Stenman UH
    Clin Chem; 1993 Oct; 39(10):2098-103. PubMed ID: 7691441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of the complex between prostate specific antigen and alpha 1-protease inhibitor for screening prostate cancer.
    Finne P; Zhang WM; Auvinen A; Leinonen J; Määttänen L; Rannikko S; Tammela TL; Stenman UH
    J Urol; 2000 Dec; 164(6):1956-60. PubMed ID: 11061890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progression of prostate cancer: diagnostic and prognostic utility of prostate-specific antigen, alpha2-macroglobulin, and their complexes.
    Kanoh Y; Ohtani N; Ohara T; Mashiko T; Ohtani S; Egawa S; Baba S; Ohtani H
    Oncol Rep; 2001; 8(3):515-9. PubMed ID: 11295072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Significance of different molecular forms of serum PSA. The free, noncomplexed form of PSA versus that complexed to alpha 1-antichymotrypsin.
    Lilja H
    Urol Clin North Am; 1993 Nov; 20(4):681-6. PubMed ID: 7505976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proportion of prostate-specific antigen (PSA) complexed to alpha(1)-antichymotrypsin improves the discrimination between prostate cancer and benign prostatic hyperplasia in men with a total PSA of 10 to 30 microg/L.
    Martínez M; España F; Royo M; Alapont JM; Navarro S; Estellés A; Aznar J; Vera CD; Jiménez-Cruz JF
    Clin Chem; 2002 Aug; 48(8):1251-6. PubMed ID: 12142381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.